William Roper - Cigna Corp Independent Director
| CI Stock | USD 291.44 3.83 1.33% |
Insider
William Roper is Independent Director of Cigna Corp since 2018.
| Age | 71 |
| Tenure | 8 years |
| Address | 900 Cottage Grove Road, Bloomfield, CT, United States, 06002 |
| Phone | 860 226 6000 |
| Web | https://www.thecignagroup.com |
Cigna Corp Management Efficiency
The company has Return on Asset (ROA) of 0.0403 % which means that for every $100 of assets, it generated a profit of $0.0403. This is way below average. Likewise, it shows a return on total equity (ROE) of 0.1513 %, which means that it produced $0.1513 on every 100 dollars invested by current stockholders. Cigna Corp's management efficiency ratios could be used to measure how well Cigna Corp manages its routine affairs as well as how well it operates its assets and liabilities. The Cigna Corp's current Return On Equity is estimated to increase to 0.10, while Return On Tangible Assets are projected to decrease to 0.02. As of now, Cigna Corp's Intangible Assets are increasing as compared to previous years. The Cigna Corp's current Intangibles To Total Assets is estimated to increase to 0.46, while Total Assets are projected to decrease to under 91.2 B.Similar Executives
| Showing other executives | INSIDER Age | ||
| PharmD MBA | GT Biopharma | N/A | |
| Maria JD | bioAffinity Technologies | 70 | |
| Xavier MS | bioAffinity Technologies | 56 | |
| HuiLan Wu | Ainos Inc | 63 | |
| Manu Ohri | GT Biopharma | 69 | |
| John Esq | Ainos Inc | 57 | |
| Carol Odle | Revelation Biosciences | N/A | |
| David Lovejoy | Protagenic Therapeutics | N/A | |
| Chester III | Revelation Biosciences | 46 | |
| Gregory MBA | Artelo Biosciences | 63 | |
| Andrew Slee | Protagenic Therapeutics | 76 | |
| James Rolke | Revelation Biosciences | 57 | |
| Jeffrey MD | GT Biopharma | N/A | |
| Robert MD | Protagenic Therapeutics | 75 | |
| Steven Reich | Artelo Biosciences | 78 | |
| Gregory MD | GT Biopharma | 66 | |
| MPH MBA | GT Biopharma | N/A | |
| Michael Breen | GT Biopharma | 62 | |
Management Performance
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0403 |
Cigna Corp Leadership Team
Elected by the shareholders, the Cigna Corp's board of directors comprises two types of representatives: Cigna Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Cigna. The board's role is to monitor Cigna Corp's management team and ensure that shareholders' interests are well served. Cigna Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Cigna Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Nicole Jones, Executive Vice President, General Counsel | ||
| Donna Zarcone, Independent Director | ||
| John Webb, President - Health Care | ||
| Alexis Jones, Investor Principal | ||
| Neesha Hathi, Independent Director | ||
| Eric Foss, Independent Director | ||
| John Murabito, Executive Vice President - Human Resources, Chief Administrative Officer | ||
| Christopher MBA, President Businesses | ||
| Roman Martinez, Independent Director | ||
| Ralph Giacobbe, Senior Relations | ||
| Phil Austin, Head Markets | ||
| Elder Granger, Independent Director | ||
| Kimberly Ross, Independent Director | ||
| Brian Evanko, Chief Financial Officer, Executive Vice President | ||
| Matt Perlberg, Pharmacy President | ||
| Kari Stevens, Executive Officer | ||
| David Cordani, CEO and President Director and Member of Executive Committee | ||
| Terese CPA, Senior Officer | ||
| Charles Berg, President - U.S. Government Business | ||
| Ann Dennison, Executive CFO | ||
| Arjan Toor, Chief Operations | ||
| Matthew Manders, President of U.S. Commercial Markets and Global Health Care Operations | ||
| Durga Koka, Executive Officer | ||
| Noelle Eder, Executive Vice President, Global Chief Information Officer | ||
| Eric Palmer, Chief Financial Officer, Executive Vice President | ||
| Dean Mirabella, President Markets | ||
| Cynthia Ryan, Chief Human Resource Officer | ||
| Mark Boxer, Executive Vice President, Chief Information Officer | ||
| Nicole JD, Chief VP | ||
| Adam PharmD, President Services | ||
| Jason Sadler, President of International Markets | ||
| Timothy Wentworth, Chief Executive Officer - Evernorth | ||
| Isaiah Harris, Independent Chairman of the Board | ||
| William DeLaney, Independent Director | ||
| Kristen Lauria, Executive Vice President, Chief Marketing Officer | ||
| Everett Neville, Executive Vice President, Strategy, Corporate Development and Solutions | ||
| David Kobus, Market Market | ||
| Paul Sanford, Executive Vice President - Operations | ||
| John Partridge, Independent Director | ||
| Jamie Kates, Chief Officer | ||
| Mark McClellan, Independent Director | ||
| Kathleen Mazzarella, Independent Director | ||
| Mary CPA, Senior Officer | ||
| MICHAEL TRIPLETT, President - U.S. Commercial | ||
| Steven Miller, Executive Vice President Chief Clinical Officer | ||
| Mary Picerno, Chief Officer | ||
| Brian CFA, President Healthcare | ||
| Eric Wiseman, Lead Independent Director | ||
| William Roper, Independent Director | ||
| George Kurian, Independent Director |
Cigna Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Cigna Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.15 | ||||
| Return On Asset | 0.0403 | ||||
| Profit Margin | 0.02 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 103.79 B | ||||
| Shares Outstanding | 263.46 M | ||||
| Shares Owned By Insiders | 1.61 % | ||||
| Shares Owned By Institutions | 92.50 % | ||||
| Number Of Shares Shorted | 4.61 M | ||||
| Price To Earning | 13.93 X |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cigna Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. For more detail on how to invest in Cigna Stock please use our How to Invest in Cigna Corp guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Is there potential for Health Care Providers & Services market expansion? Will Cigna introduce new products? Factors like these will boost the valuation of Cigna Corp. Projected growth potential of Cigna fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about Cigna Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.11) | Dividend Share 6.04 | Earnings Share 22.18 | Revenue Per Share | Quarterly Revenue Growth 0.104 |
Cigna Corp's market price often diverges from its book value, the accounting figure shown on Cigna's balance sheet. Smart investors calculate Cigna Corp's intrinsic value - its true economic worth - which may differ significantly from both market price and book value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Since Cigna Corp's trading price responds to investor sentiment, macroeconomic conditions, and market psychology, it can swing far from fundamental value.
It's important to distinguish between Cigna Corp's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Cigna Corp should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. However, Cigna Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.